Abstracts tagged "Disease Activity"

Abstract Number: 2481 • ACR Convergence 2024
General, Nervous System, Eye, and Skin Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
Rula A. Hajj-Ali¹, Duvuru Geetha², Raashid Luqmani³, Christian Pagnoux⁴, Darcy Trimpe⁵, David Jayne⁶ and Peter Merkel⁷, and ADVOCATE Study Group, ¹Cleveland Clinic, Cleveland, OH, ²Johns Hopkins University, Baltimore, MD, ³University of Oxford, Abingdon, United Kingdom, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵Amgen Inc., Thousand Oaks, CA, ⁶University of Cambridge, Cambridge, United Kingdom, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: The most common types of ANCA-associated vasculitis, granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), can affect a range of organs, including the kidneys,…
Abstract Number: 0412 • ACR Convergence 2024
Impact of Approval of Biologic DMARDs on JIA Outcomes in a Single Center
Anna Sutton¹, Erin Balay-Dustrude¹, Beth A Mueller¹ and Susan Shenoi², ¹University of Washington, Seattle, WA, ²Seattle Children's Hospital and Research Center, Mercer Island, WA, WA
Background/Purpose: In clinical trials, biologic disease-modifying antirheumatic drugs (bDMARDs) for juvenile idiopathic arthritis (JIA) have demonstrated good efficacy. However, less is known about the impact…
Abstract Number: 0569 • ACR Convergence 2024
The Longitudinal Association Between Disease Activity, Function and Health-Related Quality of Life in Axial Spondyloarthritis: Results from the DESIR Cohort
Augusta Ortolan¹, Desiree van der Heijde², Laure Gossec³ and Sofia Ramiro⁴, ¹Policlinico Universitario Agostino Gemelli IRCSS, Rome, Lazio, Italy, ²Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ³Sorbonne Université, Paris, France, ⁴Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Health-related quality of life (HRQoL) in axSpA is considered an overarching outcome, with other disease outcomes contributing to it [1]. To validate a previously…
Abstract Number: 0660 • ACR Convergence 2024
Hydroxychloroquine Users at Lower Risk of Kidney Function Decline in Lupus Nephritis
Shivani Garg¹, Brad Rovin², Brad Astor¹, Tripti Singh¹, Lexie Kolton¹, Callie Saric¹, S. Sam Lim³ and Christie Bartels⁴, ¹University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, ²The Ohio State University, Columbus, OH, ³Emory University, Atlanta, GA, ⁴University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Hydroxychloroquine (HCQ) is the cornerstone in treatment of systemic lupus erythematosus (SLE), yet its role in preventing kidney function decline in lupus nephritis (LN)…
Abstract Number: 1060 • ACR Convergence 2024
Therapeutic Hydroxychloroquine Blood Levels Predict Lower Mean Frequency of Recurrent Acute Care Utilization in Lupus
Shivani Garg¹, Giancarlo Valiente², Callie Saric¹, Betty Chewning³ and Christie Bartels⁴, ¹University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, ²University of Wisconsin, School of Medicine and Public Health, Madison, ³University of Wisconsin, School of Pharmacy, Madison, ⁴University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Nonadherence to hydroxychloroquine (HCQ) is highly prevalent in lupus (or SLE) and two-fold higher in patients of Black race or Hispanic ethnicity. While HCQ…
Abstract Number: 1342 • ACR Convergence 2024
Utility of Anti-Carbamylated Antibodies in Early Rheumatoid Arthritis in South Asian Population
chandhu aS¹, Josna Joseph¹, ABHILASHA ARVIND MANWATKAR² and John Mathew³, ¹CMC Vellore, Vellore, Tamil Nadu, India, ²christian medical college, vellore, Tamil Nadu, India, ³Christian Medical college , Vellore , India, Vellore, India
Background/Purpose: Rheumatoid Arthritis (RA) is an autoantibody mediated disease with deforming peripheral arthritis. Autoantibodies widely used are rheumatoid factor (RF) and anti-citrullinated peptide antibody (ACPA).…
Abstract Number: 1411 • ACR Convergence 2024
Impact of Patient and Physician Alignment on Sjögren’s Disease Severity, a Real-World Survey on Patients’ Clinical Outcomes and Health-Related Quality of Life
Wan Fai Ng¹, Coralie Bouillot², NICOLA MASSEY³, Megan Hughes³, Victoria Barton³, Giorgio Castellano³, Ana Barat⁴, Gayle Kenney⁵ and Jessica Marvel⁶, ¹Department of Rheumatology, Newcastle University, & HRB Clinical Research Facility, University College Cork, Newcastle upon Tyne, United Kingdom, ²Sjögren Europe, Switzerland, Switzerland, ³ADELPHI REAL WORLD, BOLLINGTON, United Kingdom, ⁴Novartis Ireland Ltd, Dublin, Ireland, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis, East Hanover, NJ
Background/Purpose: Sjögren’s disease (SjD) has a high disease burden in affected patients, with no licensed treatments currently available. The Clinical EULAR Sjögren’s syndrome disease activity…
Abstract Number: 1698 • ACR Convergence 2024
Assessment of the Remission Maintenance After Tocilizumab Withdrawal in Polymyalgia Rheumatica Patients Receiving a 6-month Treatment
Baptiste Chevet¹, Aghiles Souki², nowak emmanuel², Guillermo CARVAJAL ALEGRIA³, Emmanuelle Dernis⁴, Christophe Richez⁵, Marie-Elise Truchetet⁶, DANIEL WENDLING⁷, ERIC TOUSSIROT⁸, aleth Perdriger⁹, Jacques-Eric Gottenberg¹⁰, Renaud FELTEN¹¹, Bruno Fautrel¹², laurent chiche¹³, Anne Walliser-Lohse¹⁴, Pascal Hilliquin¹⁵, Catherine Le Henaff¹⁶, Benjamin Dervieux¹⁷, Guillaume Direz¹⁸, Isabelle Valckenaere¹⁹, Divi Cornec²⁰, Dewi Guellec²¹, Thierry Marhadou²², Alain SARAUX²³ and Valerie Devauchelle²⁴, ¹University Hospital of Brest, Brest, France, ²Centre Hospitalier Regional Universitaire (CHU) de Brest, Brest, France, ³CHRU de Tours, Tours, France, ⁴CH LE MANS, LE MANS, Pays de la Loire, France, ⁵Université de Bordeaux, Bordeaux, France, ⁶Bordeaux University Hospital, Bordeaux, France, ⁷University Hospital, Besançon, France, ⁸university hospital of BESANCON, besancon, France, ⁹Rennes University, Rennes, France, ¹⁰Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ¹¹Hopitaux Universitaires de Strasbourg, STRASBOURG, France, ¹²INSERM, UMRS 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Sorbonne University – Assistance Publique-Hôpitaux de Paris, Département de Rhumatologie, Hôpital Pitié-Salpêtrière, Paris, Ile-de-France, France, ¹³hopital europeen, marseille, France, ¹⁴Hopital Nord Franche-Comté, BELFORT, France, ¹⁵Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France, ¹⁶Hopital de Morlaix, Morlaix, France, ¹⁷CH de Mulhouse - Competence center for autoimmune diseases, Internal Medicine, Mulhouse, France, ¹⁸Hôpital du Mans, Le Mans, France, ¹⁹CHU de Nancy, Nancy, France, ²⁰Service de Rhumatologie, CHU de Brest, Brest, France, ²¹CHU de Brest, Brest, France, ²²CHU Cavale Blanche, Brest, France, ²³CHU Brest, Brest, France, ²⁴UBO, Brest, France
Background/Purpose: The SEMAPHORE trial1 was a randomized controlled prospective study to assess the safety and efficacy (success defined by PMR-AS≤10 and GC≤5mg or GC decrease…
Abstract Number: 2050 • ACR Convergence 2024
Clinical Enthesitis Concerns Half the Patients with Psoriatic Arthritis, Is More Frequent in Trials Than in Observational Studies and Is Assessed Heterogeneously: A Systematic Review with Meta-analysis of 84,262 Patients from 212 Studies
caroline pignon¹, Laure Gossec², Bruno Fautrel³, Clementina López Medina⁴ and Noemie bibas⁵, ¹Faculté de médecine Créteil, PARIS, France, ²Sorbonne Université, Paris, France, ³INSERM, UMRS 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Sorbonne University – Assistance Publique-Hôpitaux de Paris, Département de Rhumatologie, Hôpital Pitié-Salpêtrière, Paris, Ile-de-France, France, ⁴Reina Sofia University Hospital, Cordoba, Spain, ⁵Sorbonne Université, paris
Background/Purpose: Enthesitis is considered a hallmark of psoriatic arthritis (PsA), however data on the frequency and consequences of enthesitis are conflicting. To analyze clinical enthesitis in…
Abstract Number: 2356 • ACR Convergence 2024
Baseline Characteristics of Patients with Psoriatic Arthritis Treated with Ixekizumab or Interleukin-23 Inhibitors and Interim Effectiveness Results from an Observational Study in the US
KURT OELKE¹, Emily Edson Heredia², Sarah Ross², Jeffrey Lisse², Jennifer Pustizzi², Ali Sheikhi Mehrabadi², Natalia Bello², Frederick Murphy³, Shikha Singla⁴ and Siba Raychaudhuri⁵, ¹Rheumatic Disease Center, Glendale, WI, ²Eli Lilly and Company, Indianapolis, IN, ³Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁴Medical College of Wisconsin, Milwaukee, WI, ⁵UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA
Background/Purpose: Ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A, has demonstrated efficacy in treating psoriatic arthritis (PsA) in Phase 3/4 clinical trials…
Abstract Number: 2529 • ACR Convergence 2024
Improving Outcomes and Narrowing Disparities in Juvenile Idiopathic Arthritis (JIA): A Division-Wide, Equity-Focused Quality Improvement Project
Dori Abel¹, Kirsten Spichiger², Megan Roman², William Baar², Claire O'Malley², Jay Mehta¹, Terri Al'Hadi², Kerry Ferraro³, Denique Butler², Asia Wilson-Sanders², Catherine Lewis², Danielle Dodson⁴ and Jon Burnham¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, ³JIA parent and CHOP volunteer, Lower Gwynedd, PA, ⁴The Children's Hospital of Philadelphia, Philadelphia
Background/Purpose: Although new therapeutics and treat-to-target interventions have improved JIA care, pronounced racial and ethnic outcome disparities persist. At our center, the mean population-level clinical Juvenile…
Abstract Number: 0421 • ACR Convergence 2024
The Effect of Biologic Treatment for Psoriatic Arthritis and Axial Spondyloarthritis on Semen Parameters – a Longitudinal Study
Katya Meridor¹, Shimi Barda², sara Pel³, sharon Nevo², Julia Berman², daphna paran⁴, Ori Elkayam⁵ and Ari Polachek⁶, ¹Tel Aviv Medical Center, Kfar Saba, Israel, ²Tel-Aviv Medical Center, Tel-Aviv, Israel, ³Tel-Aviv Medical Center, Petah-Tikva, Israel, ⁴Tel-Aviv Medical Center, EVEN-YEHUDA, Israel, ⁵Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁶Tel-Aviv Medical Center, Tel-Aviv, Israel, Petah-Tikva, Israel
Background/Purpose: Psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) are commonly diagnosed in young males in their reproductive years. However, only a few studies have investigated…
Abstract Number: 0571 • ACR Convergence 2024
Gender-specific Performance of Disease Activity Assessment Tools in Axial Spondyloarthritis: Ancillary Analysis of the PREDICT-SpA Study
Sabrina Hamroun¹, Laure Gossec², Serge Perrot³, Maxime Dougados⁴ and Anna Molto⁵, ¹Cochin University Hospital, Paris, Ile-de-France, France, ²Sorbonne Université, Paris, France, ³Paris Dauphine University, Paris, France, ⁴Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁵Groupe Hospitalier Cochin, AP-HP, Paris, France
Background/Purpose: There are several tools for assessing disease activity in spondyloarthritis (SpA). The literature reveals gender differences, with unfavorable Patient Reported Outcomes in women compared…
Abstract Number: 0671 • ACR Convergence 2024
Effect of Litifilimab on Cutaneous Lupus Erythematosus Disease Area and Severity Index–Activity (CLASI-A) Subcomponents and Physician Global Assessment–Skin (PGA–Skin) in Patients with Cutaneous Lupus Erythematosus (CLE) in a Phase 2 Study
Victoria Werth¹, Joseph F. Merola², Qianyun Li³, Weihong Yang³ and Catherine Barbey⁴, ¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²UT Southwestern Medical Center, Dallas, TX, ³Biogen, Cambridge, MA, ⁴Biogen, Baar, Switzerland
Background/Purpose: In the randomized, placebo-controlled Phase 2 LILAC study of litifilimab (NCT02847598), Part B (participants with active CLE with/without SLE) met its primary endpoint of…
Abstract Number: 1113 • ACR Convergence 2024
2nd Analysis of IgG4-Related Disease in a Diverse Long Island Population: Utilizing Serological and Histological Markers for Assessing Treatment Response
Young Min Cho¹, Alejandro Quintero Villegas², Matt Means³, Zanos Theodoros², Lara El Khoury⁴ and Galina Marder³, ¹Northwell, Glen Cove, NY, ²Feinstein Institutes for Medical Research, Manhasset, NY, ³Northwell, Manhasset, NY, ⁴Division of Rheumatology/Northwell Health, Great Neck, NY
Background/Purpose: IgG4-RD presents various clinical manifestations, making it challenging to assess treatment responses. B-cell depletion agents such as Rituximab (RTX) are used in refractory cases.…

« Previous Page
1
…
5
6
7
8
9
…
102
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].